+

WO2002045701A3 - Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation - Google Patents

Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation Download PDF

Info

Publication number
WO2002045701A3
WO2002045701A3 PCT/US2001/046614 US0146614W WO0245701A3 WO 2002045701 A3 WO2002045701 A3 WO 2002045701A3 US 0146614 W US0146614 W US 0146614W WO 0245701 A3 WO0245701 A3 WO 0245701A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
transdermal drug
drugs
delivery systems
crystallization inhibition
Prior art date
Application number
PCT/US2001/046614
Other languages
English (en)
Other versions
WO2002045701A2 (fr
Inventor
Rod Lawson Hartwig
Original Assignee
Noven Pharma
Rod Lawson Hartwig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noven Pharma, Rod Lawson Hartwig filed Critical Noven Pharma
Priority to AU2002235155A priority Critical patent/AU2002235155A1/en
Publication of WO2002045701A2 publication Critical patent/WO2002045701A2/fr
Publication of WO2002045701A3 publication Critical patent/WO2002045701A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés permettant à un système d'administration transdermique de médicament d'atteindre une cinétique d'ordre pratiquement zéro afin d'administrer l'agent actif pendant une durée supérieure à 24 heures et d'au moins 72 heures, ce qui consiste en un véhicule d'agent actif acceptable sur le plan pharmaceutique et en un ester de colophane exerçant un effet d'inhibition de la cristallisation et de stabilisation du médicament sur les agents actifs incorporés dans ce système.
PCT/US2001/046614 2000-12-05 2001-12-05 Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation WO2002045701A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002235155A AU2002235155A1 (en) 2000-12-05 2001-12-05 Crystallization inhibition of drugs in transdermal drug delivery systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25129400P 2000-12-05 2000-12-05
US60/251,294 2000-12-05

Publications (2)

Publication Number Publication Date
WO2002045701A2 WO2002045701A2 (fr) 2002-06-13
WO2002045701A3 true WO2002045701A3 (fr) 2002-12-27

Family

ID=22951315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046614 WO2002045701A2 (fr) 2000-12-05 2001-12-05 Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation

Country Status (4)

Country Link
US (4) US20020106402A1 (fr)
AU (1) AU2002235155A1 (fr)
TW (1) TWI287455B (fr)
WO (1) WO2002045701A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541807A (en) 2003-02-21 2009-07-31 Bayer Schering Pharma Ag UV stable transdermal therapeutic plaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
CN102085198B (zh) 2004-10-21 2014-06-04 杜雷科特公司 透皮给药系统
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
KR101304982B1 (ko) * 2006-05-08 2013-09-06 (주)아모레퍼시픽 경피흡수용 조성물 및 이로부터 형성된 고분자 매트릭스함유 경피흡수제제
WO2008079440A2 (fr) 2006-07-10 2008-07-03 Medipacs, Inc. Hydrogel époxy super-élastique
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP2227635A2 (fr) 2007-12-03 2010-09-15 Medipacs, Inc. Dispositif de mesure de fluide
EP2258355B1 (fr) * 2008-02-27 2020-01-22 Hisamitsu Pharmaceutical Co., Inc. Patch
EP2255802B1 (fr) 2008-02-27 2018-01-17 Hisamitsu Pharmaceutical Co., Inc. Timbre transdermique adhésif et produit conditionné
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
WO2010027876A1 (fr) * 2008-08-26 2010-03-11 Hauser Ray L Administration de substance à la peau et autres tissus
WO2010042152A2 (fr) * 2008-10-06 2010-04-15 Mylan Technologies, Inc. Système transdermique de rotigotine amorphe
WO2011032011A1 (fr) 2009-09-10 2011-03-17 Medipacs, Inc. Actionneur à faible encombrement et méthode améliorée d'administration d'agents thérapeutiques commandée par le soignant
MX2012004550A (es) * 2009-10-21 2012-05-29 Teikoku Seiyaku Kk Formulacion de absorcion transdermica que contiene donepezil.
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PT2613772T (pt) 2010-09-06 2017-03-06 Bayer Ip Gmbh Emplastros transdérmicos de dose baixa com alta libertação de fármaco
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
KR101054317B1 (ko) * 2011-01-28 2011-08-08 신신제약 주식회사 리바스티그민을 함유하는 경피흡수제제
US9925264B2 (en) 2011-05-10 2018-03-27 Itochu Chemical Frontier Corporation Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
WO2012153396A1 (fr) 2011-05-10 2012-11-15 伊藤忠ケミカルフロンティア株式会社 Timbre non aqueux
EP3363432B1 (fr) 2011-09-27 2020-12-23 Itochu Chemical Frontier Corporation Patch non aqueux
EP2847249A4 (fr) 2012-03-14 2016-12-28 Medipacs Inc Matériaux polymères intelligents contenant un excès de molécules réactives
US20140087108A1 (en) * 2012-09-26 2014-03-27 Earth Renewable Technologies Extrudable composition derived from renewable resources and method of making molded articles utilizing the same
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464573A1 (fr) * 1990-06-25 1992-01-08 LTS LOHMANN THERAPIE-SYSTEME GmbH & CO.KG Pansement à haute teneur en substances adoucissantes
WO1995018603A1 (fr) * 1994-01-07 1995-07-13 Noven Pharmaceuticals, Inc. Dispositif d'administration transdermique contenant de la polyvinylpyrrolidone en tant qu'amplificateur de solubilite
US5478567A (en) * 1991-08-30 1995-12-26 Hisamitsu Pharmaceutical Co., Inc. Antiphlogistic analgesic plaster
EP0748629A1 (fr) * 1994-03-11 1996-12-18 Sekisui Chemical Co., Ltd. Emplatre a absorption percutanee comprenant un sel d'addition d'acide de la morphine
WO1999015156A1 (fr) * 1997-09-25 1999-04-01 Ethical Pharmaceuticals South America S.A. Inhibition de la cristallisation dans des dispositifs transdermiques
DE19830648A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Glyceroltrinitrathaltige Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung
US6143319A (en) * 1993-05-06 2000-11-07 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system containing estradiol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
JP3238409B2 (ja) * 1994-09-16 2001-12-17 久光製薬株式会社 外用貼付剤
JP3782834B2 (ja) * 1994-10-26 2006-06-07 株式会社トクホン 鎮痛抗炎症貼付剤
DE19500662C2 (de) * 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
US6063838A (en) * 1995-02-16 2000-05-16 3M Innovative Properties Company Blended pressure-sensitive adhesives
JPH0912448A (ja) * 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
JP3534775B2 (ja) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド １７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
JP3602249B2 (ja) * 1996-03-01 2004-12-15 日東電工株式会社 シート状粘着剤の貼合せ方法
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464573A1 (fr) * 1990-06-25 1992-01-08 LTS LOHMANN THERAPIE-SYSTEME GmbH & CO.KG Pansement à haute teneur en substances adoucissantes
US5478567A (en) * 1991-08-30 1995-12-26 Hisamitsu Pharmaceutical Co., Inc. Antiphlogistic analgesic plaster
US6143319A (en) * 1993-05-06 2000-11-07 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system containing estradiol
WO1995018603A1 (fr) * 1994-01-07 1995-07-13 Noven Pharmaceuticals, Inc. Dispositif d'administration transdermique contenant de la polyvinylpyrrolidone en tant qu'amplificateur de solubilite
EP0748629A1 (fr) * 1994-03-11 1996-12-18 Sekisui Chemical Co., Ltd. Emplatre a absorption percutanee comprenant un sel d'addition d'acide de la morphine
WO1999015156A1 (fr) * 1997-09-25 1999-04-01 Ethical Pharmaceuticals South America S.A. Inhibition de la cristallisation dans des dispositifs transdermiques
DE19830648A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Glyceroltrinitrathaltige Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
US20040142023A1 (en) 2004-07-22
US20030152616A1 (en) 2003-08-14
US20020106402A1 (en) 2002-08-08
TWI287455B (en) 2007-10-01
WO2002045701A2 (fr) 2002-06-13
US20080063698A1 (en) 2008-03-13
AU2002235155A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO2002045701A3 (fr) Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation
WO2000074661A3 (fr) Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation
WO2002015903A3 (fr) Nouvelle composition pharmaceutique permettant l'administration de n-0923
WO2001052823A3 (fr) Compositions et methodes permettant d'elaborer un profil de liberation dans l'administration transdermique d'agents actifs
IL148127A0 (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
CA2126611A1 (fr) Formulations d'opioides a liberation prolongee
MXPA03011910A (es) Suministro de medicamento mejorado en sistemas transdermicos.
WO1999013862A3 (fr) Composition pharmaceutique destinee au traitement des dysmenorrhees et de l'accouchement premature
WO1999053910A3 (fr) Compositions pharmaceutiques contenant de l'acide folique, procedes et systemes d'administration correspondants
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
AU2274201A (en) Compounds and compositions for delivering active agents
AU3357800A (en) Method of preparing alkylated salicylamides
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
EP1093819A3 (fr) Composés et compositions pour l'administration d'agents actifs
MY148475A (en) Controlled release preparations comprising tramadol and topiramate
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
IL108234A0 (en) Pharmaceutical composition containing galanthamine
WO2002004409A3 (fr) Agents neuroprotecteurs à base d'analogues de tétrahydrobenzothiazole
WO2001098364A3 (fr) Peptides, compositions et methodes de traitement de burkholderia cepacia
WO2002015892A3 (fr) Combinaisons
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
CA2331414A1 (fr) Systeme therapeutique transdermique pour administration de candesartan
WO2003101380A3 (fr) Combinaison de therapies permettant de traiter la sclerose amyotrophique laterale (als) a l'aide d'inhibiteur(s) de la cyclooxygenase-2 (cox 2) et d'un second medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载